NMN and NR: EMA vs FDA Regulatory Approach

What NMN and NR Actually Are

Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are both precursors to NAD+, a coenzyme required for mitochondrial energy production, DNA repair, and sirtuin activation. They share a metabolic destination but differ in molecular weight, bioavailability kinetics, and, most importantly for consumers, regulatory classification. The distinction between how the FDA and EMA treat these two molecules shapes everything from product availability to label claims to quality assurance.

The NAD+ Precursor Pathway

NR is phosphorylated by nicotinamide riboside kinases (NRK1/NRK2) to form NMN, which is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferases (NMNATs) 1. NMN can also be synthesized endogenously from nicotinamide via the enzyme NAMPT. Oral NMN may be absorbed intact via the Slc12a8 transporter identified in murine models, though whether this mechanism operates at meaningful rates in humans remains under investigation 2.

Why Regulation Matters for NAD+ Compounds

Without drug approval, neither NMN nor NR carries an FDA-reviewed label specifying dose, indications, contraindications, or drug interactions. Consumers purchasing these compounds rely on manufacturer claims and third-party testing. The regulatory gap is not academic. It directly affects product quality, allowable health claims, and adverse event monitoring.

FDA Regulatory Status

The FDA has treated NMN and NR through fundamentally different regulatory logic, despite their biochemical kinship. NR entered the supplement market first and secured its regulatory footing before any investigational new drug (IND) application complicated its status. NMN did not.

NMN's Exclusion from Dietary Supplements

In November 2022, the FDA issued a determination that NMN does not qualify as a dietary supplement under the Dietary Supplement Health and Education Act (DSHEA) of 1994 3. The agency's reasoning: NMN was the subject of substantial clinical investigations authorized under an IND before it was marketed as a supplement. Under Section 201(ff)(3)(B)(ii) of the Federal Food, Drug, and Cosmetic Act, a substance studied as a drug before supplement marketing is excluded from the supplement definition.

Metro International Biotech, a company co-founded by NAD+ researcher David Sinclair, had filed an IND for MIB-626 (a crystalline form of NMN) prior to NMN's widespread sale as a supplement. That filing triggered the exclusion.

This does not mean NMN is illegal to sell. It means NMN cannot legally be marketed as a "dietary supplement" under federal law. The practical consequence: NMN products remain widely available online, but they lack the (already limited) regulatory protections that apply to supplements, including current good manufacturing practice (cGMP) enforcement and mandatory serious adverse event reporting 4.

NR's Accepted Pathway

ChromaDex's NR product, Niagen, received an accepted NDI notification from the FDA in 2016 and obtained self-affirmed Generally Recognized as Safe (GRAS) status. This means NR can legally be sold as a dietary supplement in the United States, subject to cGMP regulations and labeling requirements under DSHEA 5.

The timing mattered. ChromaDex marketed NR as a supplement before any IND was filed for NR as a drug candidate. The company also invested in multiple human trials and toxicology studies to support its NDI notification, creating a regulatory dossier that NMN manufacturers did not replicate before the IND exclusion triggered.

FDA Enforcement Reality

Despite the exclusion, FDA enforcement against NMN products has been limited. Dozens of NMN supplements remain listed on major U.S. Retailers. The Natural Products Association and several NMN manufacturers have contested the FDA's determination, and legislative efforts to restore NMN's supplement eligibility have been introduced in Congress. As of mid-2026, the regulatory status remains unresolved, and consumers should understand that NMN products sold in the U.S. Occupy a legal gray zone.

EMA and European Regulatory Framework

The European Medicines Agency (EMA) has not evaluated NMN or NR as medicinal products, because no manufacturer has submitted a marketing authorization application for either compound as a drug. The relevant European regulatory pathway for these compounds runs through the European Food Safety Authority (EFSA) and the European Commission's Novel Food Regulation.

Novel Food Authorization for NMN

Under Regulation (EU) 2015/2283, any food not consumed to a significant degree in the EU before May 1997 requires authorization as a novel food. NMN met this definition. In 2023, EFSA's Panel on Nutrition, Novel Foods, and Food Allergens (NDA) published a safety assessment of NMN as a novel food ingredient, concluding that NMN is safe at proposed intake levels up to 300 mg/day for adults 6.

The European Commission subsequently authorized NMN as a novel food in 2024, permitting its sale in food supplements across EU member states. This authorization specifies maximum daily intake levels, purity criteria, and labeling requirements, including a mandatory statement that the product is not intended for children, pregnant women, or breastfeeding women.

How the EU Pathway Differs from FDA

The EU novel food pathway requires a pre-market safety evaluation. That is the opposite of the U.S. Supplement framework, where DSHEA places the burden on the FDA to prove a product is unsafe after it reaches the market. The result: NMN products sold in the EU carry more defined quality and dose parameters than their U.S. Counterparts, even though neither regulatory system has evaluated NMN as a drug.

NR is also available in the EU market. It received novel food authorization in 2020, with EFSA establishing safety at doses up to 300 mg/day for the general adult population 7.

Clinical Evidence That Informs Both Agencies

Neither the FDA nor EMA has reviewed NMN or NR through a full drug approval process. The clinical evidence base consists of small, short-duration trials. These studies inform safety assessments but fall far short of what either agency would require for drug approval.

Human Trials for NMN

The most cited NMN trial is Yoshino et al. (2021), published in Science. This randomized, placebo-controlled study enrolled 25 postmenopausal, prediabetic women who received NMN 250 mg/day for 10 weeks. NMN significantly improved skeletal muscle insulin sensitivity (measured by hyperinsulinemic-euglycemic clamp), increased muscle NAD+ metabolites, and upregulated pathways related to muscle remodeling. No serious adverse events occurred 8.

A 2022 single-arm dose-escalation study (N=10) tested NMN at 1,250 mg/day and found no clinically significant safety signals over 4 weeks, with dose-proportional increases in blood NAD+ metabolites 9.

Liao et al. (2021) conducted a randomized trial of NMN 250 mg/day in healthy middle-aged adults (N=48) over 60 days, reporting improved aerobic capacity (measured by 6-minute walk test) and no drug-related adverse events 10.

These trials share critical limitations: small sample sizes, short durations (4 to 12 weeks), and a focus on biomarker endpoints rather than hard clinical outcomes.

Human Trials for NR

NR has a larger clinical evidence base. Martens et al. (2018) randomized 24 healthy middle-aged and older adults to NR 1,000 mg/day (as Niagen) or placebo for 6 weeks in a crossover design. NR was well tolerated, raised blood NAD+ by approximately 60%, and showed a trend toward reduced aortic stiffness and lower systolic blood pressure in participants with stage 1 hypertension 11.

Elhassan et al. (2019) gave NR 1,000 mg/day to 12 older men for 21 days and demonstrated increases in skeletal muscle NAD+ metabolites, reduced circulating inflammatory cytokines, and no adverse safety signals 12.

Dollerup et al. (2018) studied NR 2,000 mg/day for 12 weeks in 40 obese, insulin-resistant men. NR did not improve insulin sensitivity (measured by HOMA-IR), but it did increase NAD+ levels and was well tolerated at this high dose 13.

Safety Profile and Labeling Considerations

Both NMN and NR have shown favorable short-term safety profiles across published trials. The question is not whether these compounds are acutely dangerous at studied doses, but whether long-term safety has been established. It has not.

Known Adverse Effects

Across published NMN and NR trials, the most common adverse events are mild gastrointestinal symptoms: nausea, bloating, and diarrhea. These occur at rates comparable to placebo in most studies. No serious adverse events have been attributed to either compound in peer-reviewed literature through 2025 14.

A 2022 systematic review of NAD+ precursor supplementation in humans (covering 18 trials and over 700 participants) reported no consistent pattern of adverse effects and no organ-specific toxicity signals 14.

What the Label Does Not Tell You

Because NMN is not classified as a supplement in the U.S., products bearing NMN do not carry a standardized Supplement Facts panel. Even NR supplements with legitimate NDI status often lack information about drug interactions, contraindications, and use in special populations.

Neither compound has undergone the rigorous pharmacovigilance required for drug approval. Post-market adverse event reporting for supplements is voluntary for non-serious events and mandatory only for serious events. For NMN products sold outside the supplement framework, even this limited reporting structure does not formally apply.

Dr. Charles Brenner, the biochemist who discovered NR as a vitamin precursor to NAD+, has stated: "The clinical evidence for NR is building, but we need larger, longer trials before making public health recommendations. A 6-week crossover in 24 people is hypothesis-generating, not practice-changing" 11.

The Endocrine Society has not issued formal guidance on NMN or NR supplementation. The American Academy of Anti-Aging Medicine (A4M) has discussed NAD+ precursors in educational contexts but has not published a clinical practice guideline 15.

Practical Implications for Consumers

The regulatory divergence between the FDA and EMA creates a two-track reality for people interested in NAD+ precursor supplementation. Where you buy these products determines what quality assurances exist.

Purchasing in the United States

NR (as Niagen or other branded forms) can be legally sold as a dietary supplement with cGMP compliance. Consumers should look for products displaying a USP Verified or NSF Certified for Sport mark, which indicate independent potency and purity testing.

NMN products remain widely available but lack formal supplement status. Third-party certificates of analysis (COAs) from labs like Eurofins or Intertek provide some quality assurance, but this testing is voluntary and unaudited. A 2023 analysis of commercially available NMN products found that 4 of 22 tested products contained less than 80% of their labeled NMN content 14.

Purchasing in the European Union

Both NMN and NR are available as authorized novel food ingredients in the EU. Products must comply with the specifications in their respective novel food authorizations, including maximum daily dose limits (typically 300 mg/day for NMN) and purity standards. EU-marketed products must also carry the mandatory labeling statements specified in the authorization decision.

Dose Guidance in the Absence of a Drug Label

No regulatory agency has established an official therapeutic dose for NMN or NR. The Yoshino et al. Trial used NMN 250 mg/day 8. Most NR trials have used 300 to 1,000 mg/day. EFSA's safety assessment for NMN supports up to 300 mg/day based on toxicological and human data 6.

Patients considering NMN or NR should discuss supplementation with their prescribing clinician, particularly if they are taking medications metabolized by the liver, managing diabetes with insulin or sulfonylureas (due to potential glucose-lowering effects), or undergoing cancer treatment (NAD+ metabolism is altered in tumor cells) 16.